cu cpt22 Search Results


cu cpt22  (MedChemExpress)
94
MedChemExpress cu cpt22
PFFs activated primary microglia by binding to TLR1/2 or TLR4. Primary microglia were pretreated with <t>Cu-CPT22,</t> resatorvid, or E6446 for 12 h and then treated with PFFs for further 24 h. Levels of TNF α (a) and IL-1 β (b) were measured by ELISA assay. (c-f) Expressions of IRAK1, TRAF6, p-IKK α / β /IKK α / β ratio, and p-NF- κ B/NF- κ B ratio were measured by Western blot. (g) Translocations of NF- κ B were monitored by immunofluorescence staining. Scale bar = 15 μ m. The values were expressed as mean ± SEM. ∗∗∗ p < 0.001.
Cu Cpt22, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/CU-CPT22/pmc06512043-34-0-11
Average 94 stars, based on 1 article reviews
cu cpt22 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cu cpt22  (TargetMol)
93
TargetMol cu cpt22
Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), <t>or</t> <t>CU‐CPT22</t> (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.
Cu Cpt22, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/CU-CPT22/pmc12527988-227-25-29
Average 93 stars, based on 1 article reviews
cu cpt22 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
cu cpt22  (Tocris)
94
Tocris cu cpt22
Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), <t>or</t> <t>CU‐CPT22</t> (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.
Cu Cpt22, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/CU+CPT+22/pm28570013-279-28-29
Average 94 stars, based on 1 article reviews
cu cpt22 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
tlr2 inhibition  (Selleck Chemicals)
93
Selleck Chemicals tlr2 inhibition
Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), <t>or</t> <t>CU‐CPT22</t> (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.
Tlr2 Inhibition, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/Cu-CPT22/pm42887494-469-1-4
Average 93 stars, based on 1 article reviews
tlr2 inhibition - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
cu-cpt22  (Merck KGaA)
90
Merck KGaA cu-cpt22
Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), <t>or</t> <t>CU‐CPT22</t> (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.
Cu Cpt22, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/cu+cpt22/pmc06481764-162-14-15
Average 90 stars, based on 1 article reviews
cu-cpt22 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cu cpt 22  (GlpBio Technology Inc)
90
GlpBio Technology Inc cu cpt 22
Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), <t>or</t> <t>CU‐CPT22</t> (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.
Cu Cpt 22, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/cu+cpt+22/pm35659940-233-5-11
Average 90 stars, based on 1 article reviews
cu cpt 22 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tlr2 specific inhibitor cu cpt22  (Bomac Laboratories Limited)
86
Bomac Laboratories Limited tlr2 specific inhibitor cu cpt22
Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), <t>or</t> <t>CU‐CPT22</t> (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.
Tlr2 Specific Inhibitor Cu Cpt22, supplied by Bomac Laboratories Limited, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cu+cpt22/cpt22+cu+inhibitor+specific+tlr2/pm41478530-77-45-39
Average 86 stars, based on 1 article reviews
tlr2 specific inhibitor cu cpt22 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
cu cpt 22  (Cayman Chemical)
N/A
CU CPT 22
   Buy from Supplier
cu-cpt22  (MuseChem Chemicals)
N/A
CU CPT 22(cas# 1416324-85-0) is a selective toll-like receptor 1/2 (TLR1/2) inhibitor (IC50 = 0.58 μM), exhibits no activity at TLR2/TLR6, TLR3, TLR4 and TLR7 or a panel of 10 representative kinases. CU CPT 22
   Buy from Supplier
cu cpt 22  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier
cu cpt 22  (BOC Sciences)
N/A
CU CPT 22 is a selective TLR1/2 inhibitor (IC50 = 0.58 μM).
   Buy from Supplier

Image Search Results


PFFs activated primary microglia by binding to TLR1/2 or TLR4. Primary microglia were pretreated with Cu-CPT22, resatorvid, or E6446 for 12 h and then treated with PFFs for further 24 h. Levels of TNF α (a) and IL-1 β (b) were measured by ELISA assay. (c-f) Expressions of IRAK1, TRAF6, p-IKK α / β /IKK α / β ratio, and p-NF- κ B/NF- κ B ratio were measured by Western blot. (g) Translocations of NF- κ B were monitored by immunofluorescence staining. Scale bar = 15 μ m. The values were expressed as mean ± SEM. ∗∗∗ p < 0.001.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Triptolide Inhibits Preformed Fibril-Induced Microglial Activation by Targeting the MicroRNA155-5p/SHIP1 Pathway

doi: 10.1155/2019/6527638

Figure Lengend Snippet: PFFs activated primary microglia by binding to TLR1/2 or TLR4. Primary microglia were pretreated with Cu-CPT22, resatorvid, or E6446 for 12 h and then treated with PFFs for further 24 h. Levels of TNF α (a) and IL-1 β (b) were measured by ELISA assay. (c-f) Expressions of IRAK1, TRAF6, p-IKK α / β /IKK α / β ratio, and p-NF- κ B/NF- κ B ratio were measured by Western blot. (g) Translocations of NF- κ B were monitored by immunofluorescence staining. Scale bar = 15 μ m. The values were expressed as mean ± SEM. ∗∗∗ p < 0.001.

Article Snippet: Cu-CPT22, resatorvid, E6446, and 3 α -aminocholestane (3AC) were purchased from MedchemExpress (New Jersey, USA).

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Immunofluorescence, Staining

Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), or CU‐CPT22 (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.

Journal: iMeta

Article Title: Akkermansia muciniphila ‐derived hypoacylated rough‐type lipopolysaccharides alleviate diet‐induced obesity via activation of TLR4−IL‐23−IL‐22 immune axis

doi: 10.1002/imt2.70066

Figure Lengend Snippet: Akkermansia muciniphila LPS (ALPS) activates the TLR4–IL‐23–IL‐22 signaling pathway. (A) (i) Flow cytometric analysis of IL‐22 production in RORγt + ILC3 cells. (ii) Proportion of IL‐22 + RORγt + ILC3 cells among total RORγt + ILC3 cells. (B) Plasma IL‐23 levels. (C) (i) Concentration of IL‐23 in the supernatant of bone marrow–derived macrophages (BMDMs). (ii) Concentration of IL‐23 in the supernatant of bone marrow–derived dendritic cells (BMDCs). # DMSO versus ELPS; *DMSO versus ALPS. (D–F) Concentrations of IL‐23 (D), IL‐6 (E), and TNF‐α (F) in BMDMs supernatant after pretreatment with TAK242 (TLR4 antagonist, 10 μM), C29 (TLR2 antagonist, 50 μM), or CU‐CPT22 (TLR2/1 antagonist, 25 μM) for 1 h, followed by stimulation with ALPS or ELPS (100 ng/mL) for 24 h. (G) Immunofluorescent staining of TLR2 and TLR4 in BMDMs after incubation with ALPS or ELPS (1 μg/mL) for 7 h (scale bar, 20 μm). Shown are representative results from three replicates. (H) TLR4 signaling activity of ALPS was evaluated using HEK‐Blue™ reporter cells expressing mouse TLR4 (mTLR4). (I) Plasma IL‐23 levels in Tlr4 − / − mice. (J) Plasma IL‐22 levels in Tlr4 − / − mice. MOD: Model group, the high‐fat diet group. ALPS: A. muciniphila LPS group, ALPS‐treated high‐fat diet group. ALPS (In vitro): A. muciniphila LPS‐treated cells group, ELPS (In vitro): E. coli LPS‐treated cells group. ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001. Unpaired t ‐test in A–F, and H–J. n values: (A) n = 4, (B) n = 10, (C–G) n = 3, (H) n = 5, (I–J) n = 3–8.

Article Snippet: For inhibitor assay, BMDMs were seeded into 24‐well plates and preincubated with 10 μM TAK242 (HY‐11109; MedChemExpress), 50 μM C29 (HY‐100461; MedChemExpress), or 25 μM CU‐CPT22 ( T15020 ; TargetMol) for 1 h, respectively.

Techniques: Clinical Proteomics, Concentration Assay, Derivative Assay, Staining, Incubation, Activity Assay, Expressing, In Vitro